Novel Neuro3d antidepressant enters clinic

ND7001 acts on a new target that has never been associated with depression or anxiety. It is the first representative of a new generation of psycho-active compounds potentially devoid of several problems seen with existing treatments.

“Due to its entirely novel mechanism of action, ND7001 possesses certain attributes that, if translated and confirmed in humans, could result in a completely new option for patients allowing the simultaneous treatment of depression and anxiety,” noted Charles Woler, CEO of Neuro3d.

Initially, a double-blind, placebo-controlled, single, dose-escalation study will be conducted to investigate safety, tolerability and pharmacokinetics. Thereafter, a multiple-dose study will be conducted which will also include qEEG recordings to provide evidence of central nervous system (CNS) effects and active dose range.

“ND7001 is the first drug of its kind to enter clinical development,” commented Cesare Mondadori, CSO of Neuro3d. “The drug acts via a new mechanism and is well tolerated in preclinical studies. Our studies in animals show that ND7001 not only meets the criteria of an antidepressant but also of an anxiolytic compound.”